Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.

@article{Coude2012UndetectableMR,
  title={Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.},
  author={M. M. Coude and Odile Luycx and Marie-Estelle Cariou and Odile Maarek and Herv{\'e} Dombret and J. -M. Cayuela and Delphine Rea},
  journal={British journal of haematology},
  year={2012},
  volume={157 3},
  pages={407-10}
}